Trimetazidine Hydrochloride IP 35 mg is a cardio-protective agent widely used in the management of angina pectoris and other heart-related conditions. It works by improving myocardial glucose utilization, thereby enhancing the efficiency of heart cells under oxygen-deficient conditions. Unlike conventional anti-anginal drugs, Trimetazidine does not significantly affect heart rate or blood pressure, making it a preferred option for patients requiring metabolic support for the heart. This medication helps reduce the frequency and severity of anginal attacks and can improve exercise tolerance in patients with stable angina. It is often prescribed as part of a combination therapy alongside standard cardiovascular treatments.
